PROGNOSTIC VALUE OF pSTAT3 EXPRESSION IN DIFFUSIVE B-LARGE CELL LYMPHOMA IN THE RUSSIAN PATIENT SAMPLE
The aim of the study was to evaluate the prognostic value of pSTAT3 expression in diffuse B-large cell lymphoma (DLBCL) in a Russian sample of patients. Material and methods. Retrospectively, the results of an examination of 50 patients with newly diagnosed DLBCL in the period from 2014 to 2017 were evaluated. Using immunohistochemical and morphometric methods, the relative number of tumor cells expressing pSTAT3 was determined. The relationship of various levels of marker expression with clinical and laboratory parameters was analyzed, and long-term results of patient therapy were evaluated. Results and discussion. The overexpression of pSTAT3 protein is associated with a non-GCB subtype of the disease, an advanced stage, the patients of 60 years and older age, as well as with a lower frequency of achieving complete remissions with DLBCL. Patients with a high degree of marker expression in tumor cells had lower rates of overall (OS) and progressive survival (PFS). It was revealed that the marker under study has good predictive ability, but is not an independent prognosis factor for DLBCL. Conclusions. The level of expression of pSTAT3 is an informative factor that allows predicting the response to standard therapy for diffuse B-large cell lymphoma. The indicated marker may be useful for identifying patients who need individualization of therapeutic tactics for this disease.
About Authors (Correspondence):
Vaneeva E.V., e-mail: firstname.lastname@example.org